Project Grant R01CA281216
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$521K
Federal Agency
National Cancer Institute
Awardee
Purdue University (YRXVL4JYCEF5)
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Indiana, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $700,690 to Health Research, Inc. to decipher the molecular mechanisms underlying breast cancer bone metastasis. The primary objectives are to: 1) determine the molecular mechanisms driving the dynamic activation of the transcriptional coactivators YAP/TAZ in breast cancer bone metastases, and 2) understand the functional role of YAP/TAZ-activation-driven metabolic reprogramming...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), is supporting the development and validation of a novel in vitro cancer metastasis model system using decellularized organ tissue biomatrices. The $544,475 award to the University of Texas Southwestern Medical Center aims to create a comprehensive panel of organ-specific biomatrices that can recapitulate the microenvironment and organ-specificity of cancer metastasis. The...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $648,428 to The Leland Stanford Junior University to conduct research on tumor microenvironmental biomarkers of breast cancer invasion. The key objectives are to: Identify features of the ductal carcinoma in situ (DCIS) cells and the collagen stroma that are spatially correlated with invasion, determine which of those features are causal drivers of invasion, and assess...
This National Science Foundation Project Grant of $299,785 will fund research into the integrated effects of mechanical and biochemical factors on breast tumor invasion and metastasis. Awarded on September 1, 2022 under the Engineering program (CFDA 47.041), the grant supports a collaborative research project led by the University of Michigan from September 1, 2022 through August 31, 2025. Specifically, the research team will develop quantitative imaging biosensors and tissue-engineered breast...
The federal Project Grant award R01CA286566, totaling $577,034.00, was provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Sloan-Kettering Institute for Cancer Research in New York. The grant supports research to investigate the interplay between the mechanical properties of the metastatic microenvironment and the immune system's ability to detect and suppress the growth of metastatic cancer cells. The research aims to determine how environmental stiffness...
This $612,288 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will fund research by the University of Wisconsin-Madison to investigate the role of elevated collagen I and fibronectin in the ovarian cancer pre-metastatic niche for high-grade serous ovarian cancer (HGSOC). The 5-year project aims to advance the understanding of molecular, cellular, and metabolic processes contributing to HGSOC progression and metastasis, with the goal of informing...
This federal Project Grant award of $378,444 from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), aims to investigate the role of Heat Shock Factor 1 (HSF1) in regulating immune cell infiltration into metastatic breast tumors. The overarching goal is to understand how HSF1 activity in metastatic breast cancer suppresses the recruitment of antitumor CD8+ T cells, and to evaluate the efficacy of targeting HSF1 to enhance the response of metastatic...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research aimed at understanding the molecular mechanisms underlying breast cancer plasticity and heterogeneity. The $472,921 award to the University of Utah, with a project period from February 1, 2025 to January 31, 2030, will investigate the role of the CR1 signaling pathway in regulating cancer cell state changes and interactions with the tumor microenvironment during breast...
This federal Project Grant award of $545,983 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at Northwestern University to identify molecular regulators of circulating tumor cell (CTC) interactions with the host immune system, with a focus on triple-negative breast cancer (TNBC). The key objectives are to: Determine the clinical relevance of the PlexinB2 (PB2) protein network in TNBC, as PB2 drives CTC cluster formation and interactions with...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) aims to elucidate the comprehensive mechanism of how metastatic breast cancer cells induce permeability of the blood-brain barrier (BBB), thereby facilitating breast cancer brain metastasis (BCBM). The $479,591 award, active from March 1, 2025 to February 28, 2030, is being provided to the University of Illinois in Chicago. The project will investigate how cancer-derived glycosylated...